Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled trial of IONIS PKK-LRx in hereditary angioedema
2019-001044-22Phase 2Unknown
- Sponsor
- Ionis Pharmaceuticals
- Start
- May 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of donidalorsen in hereditary angioedema (HAE), sponsored by Ionis Pharmaceuticals. Status: unknown.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2019-001044-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001044-22.